Clareo Health | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sinocelltech Ltd.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-80 years old
Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
A measurable or evaluable disease at the time of enrolment
ECOG PS 0-2
Adequate organ function and bone marrow function
Expected survival ≥ 6 months
You may not be if
Documented refractoriness to lenalidomide.
Have lenalidomide exposure within 12 months prior to randomization
